{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:33:13Z","timestamp":1793295193414,"version":"4.5.0"},"reference-count":49,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Joint Global Health Trials Scheme by DFID","award":["MR\/R006113\/1"],"award-info":[{"award-number":["MR\/R006113\/1"]}]},{"name":"NIHR Academic Clinical Lectureship at London School of Hygiene & Tropical Medicine","award":["CL-2018-20-001"],"award-info":[{"award-number":["CL-2018-20-001"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["MR\/R006113\/1"],"award-info":[{"award-number":["MR\/R006113\/1"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Doctoral Program for World-leading Innovative and Smart Education for Global Health, Nagasaki University"},{"name":"Meningitis Now and Medical Research Foundation","award":["MRF-131-0003-RB-BASU-C0851"],"award-info":[{"award-number":["MRF-131-0003-RB-BASU-C0851"]}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["MR\/R006113\/1"],"award-info":[{"award-number":["MR\/R006113\/1"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_12023\/26"],"award-info":[{"award-number":["MC_UU_12023\/26"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R006113\/1"],"award-info":[{"award-number":["MR\/R006113\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,3,11]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Childhood tuberculous meningitis (TBM) is a devastating disease. The long-standing WHO recommendation for treatment is 2 months of intensive phase with isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E), followed by 10 months of isoniazid and rifampicin. In 2022, WHO released a conditional recommendation that 6 months of intensified antituberculosis therapy (ATT) could be used as an alternative for drug-susceptible TBM. However, this has never been evaluated in a randomised clinical trial. Trials evaluating ATT shortening regimens using high-dose rifampicin and drugs with better central nervous system penetration alongside adjuvant anti-inflammatory therapy are needed to improve outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:underline>S<\/jats:underline>\n                      hortened Intensive Therapy for Children with T\n                      <jats:underline>u<\/jats:underline>\n                      be\n                      <jats:underline>r<\/jats:underline>\n                      culous M\n                      <jats:underline>e<\/jats:underline>\n                      ningitis (SURE) trial is a phase 3, randomised, partially blinded, factorial trial being conducted in Asia (India and Vietnam) and Africa (Uganda, Zambia and Zimbabwe). It is coordinated by the Medical Research Council Clinical Trial Unit at University College London (MRCCTU at UCL). 400 children (aged 29 days to &lt;18 years) with clinically diagnosed TBM will be randomised, using a factorial design, to either a 24-week intensified regimen (isoniazid (20 mg\/kg), rifampicin (30 mg\/kg), pyrazinamide (40 mg\/kg) and levofloxacin (20 mg\/kg)) or the standard 48-week ATT regimen and 8 weeks of high-dose aspirin or placebo. The primary outcome for the first randomisation is all-cause mortality, and for the second randomisation is the paediatric modified Rankin Scale (mRS), both at 48 weeks. Nested substudies include pharmacokinetics, pharmacogenetics, pathophysiology, diagnostics and prognostic biomarkers, in-depth neurodevelopmental outcomes, MRI and health economics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Local ethics committees at all participating study sites and respective regulators approved the SURE protocol. Ethics approval was also obtained from UCL, UK (14935\/001). Informed consent from parents\/carers and assent from age-appropriate children are required for all participants. Results will be published in international peer-reviewed journals, and appropriate media will be used to summarise results for patients and their families and policymakers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN40829906\">ISRCTN40829906<\/jats:ext-link>\n                      (registered 13 November 2018).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-088543","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T02:17:10Z","timestamp":1743646630000},"page":"e088543","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitis"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"isrctn40829906","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9247-4267","authenticated-orcid":false,"given":"Julie","family":"Huynh","sequence":"first","affiliation":[{"name":"Oxford University Clinical Research Unit, Ho Chi Minh City, Ho Chi Minh, Vietnam"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford OX1 4BH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chishala","family":"Chabala","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Zambia, Lusaka, Zambia"},{"name":"University Teaching Hospitals-Children's Hospital, Lusaka, Zambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvasini","family":"Sharma","sequence":"additional","affiliation":[{"name":"Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Choo","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Sankhyan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda","family":"Mujuru","sequence":"additional","affiliation":[{"name":"University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhung","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung Huu","family":"Trinh","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital 2, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuc Huu","family":"Phan","sequence":"additional","affiliation":[{"name":"Paediatric Intensive Care, Vietnam National Children\u2019s Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Viet","family":"Nhung","sequence":"additional","affiliation":[{"name":"The National Lung Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kafula Lisa","family":"Nkole","sequence":"additional","affiliation":[{"name":"University Teaching Hospitals-Children's Hospital, Lusaka, Zambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-307X","authenticated-orcid":false,"given":"Titiksha","family":"Sirari","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine","family":"Mutata","sequence":"additional","affiliation":[{"name":"University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Frangou","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Griffiths","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wobudeya","sequence":"additional","affiliation":[{"name":"Makerere University\u2014John Hopkins University Research Collaboration, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Muller","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Santana","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Kestelyn","sequence":"additional","affiliation":[{"name":"Oxford University Clinical Research Unit, Ho Chi Minh City, Ho Chi Minh, Vietnam"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford OX1 4BH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam Van","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Center for Tropical Diseases, Vietnam National Children's Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Oxford University Clinical Research Unit, Ho Chi Minh City, Ho Chi Minh, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Tran","sequence":"additional","affiliation":[{"name":"Oxford University Clinical Research Unit, Ho Chi Minh City, Ho Chi Minh, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Seddon","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Imperial College London, London, UK"},{"name":"Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Capetown, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Turkova","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Abarca-Salazar","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, London, UK"},{"name":"Clinical Research Department, London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Basu-Roy","sequence":"additional","affiliation":[{"name":"Blizard Institute, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy E","family":"Thwaites","sequence":"additional","affiliation":[{"name":"Oxford University Clinical Research Unit, Ho Chi Minh City, Ho Chi Minh, Vietnam"},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Oxford University, Oxford OX1 4BH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Crook","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne T","family":"Anderson","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M","family":"Gibb","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2025121400300790000_15.4.e088543.1","unstructured":"World Health Organisation . Global tuberculosis report. Geneva World health organisation 2024; 2024."},{"key":"2025121400300790000_15.4.e088543.2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5588\/ijtldopen.23.0529","article-title":"Global reporting on TB in children and adolescents: how far have we come and what remains to be done?","volume":"1","author":"Verkuijl","year":"2024","journal-title":"IJTLD Open"},{"key":"2025121400300790000_15.4.e088543.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70852-7"},{"key":"2025121400300790000_15.4.e088543.4","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-7-140","article-title":"Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases","volume":"7","author":"Schaaf","year":"2007","journal-title":"BMC Infect Dis"},{"key":"2025121400300790000_15.4.e088543.5","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/fms031"},{"key":"2025121400300790000_15.4.e088543.6","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/48.5.294"},{"key":"2025121400300790000_15.4.e088543.7","doi-asserted-by":"publisher","DOI":"10.1093\/tropej\/fmp080"},{"key":"2025121400300790000_15.4.e088543.8","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9040857","article-title":"Defeating Paediatric Tuberculous Meningitis: Applying the WHO 'Defeating Meningitis by 2030: Global Roadmap'","volume":"9","author":"Basu Roy","year":"2021","journal-title":"Microorganisms"},{"key":"2025121400300790000_15.4.e088543.9","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11010038","article-title":"Tuberculous Meningitis in Children: Reducing the Burden of Death and Disability","volume":"11","author":"Huynh","year":"2021","journal-title":"Pathogens"},{"key":"2025121400300790000_15.4.e088543.10","unstructured":"World health organization . Rapid advice: treatment of tuberculosis in children. 2010. Available: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44444\/9789241500449_eng.pdf?sequence=1"},{"key":"2025121400300790000_15.4.e088543.11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05429-11"},{"key":"2025121400300790000_15.4.e088543.12","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12003"},{"key":"2025121400300790000_15.4.e088543.13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","article-title":"Cerebrospinal fluid concentrations of antituberculosis agents in adults and children","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"2025121400300790000_15.4.e088543.14","first-page":"704","article-title":"Intensive short course chemotherapy in the management of tuberculous meningitis","volume":"2","author":"Donald","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025121400300790000_15.4.e088543.15","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000065"},{"key":"2025121400300790000_15.4.e088543.16","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac108","article-title":"Comparative Effectiveness of Regimens for Drug-Susceptible Tuberculous Meningitis in Children and Adolescents: A Systematic Review and Aggregate-Level Data Meta-Analysis","volume":"9","author":"Sulis","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025121400300790000_15.4.e088543.17","unstructured":"WHO operational handbook on tuberculosis . Module 5: management of tuberculosis in children and adolescents. Geneva World Health Organization; 2022."},{"key":"2025121400300790000_15.4.e088543.18","unstructured":"WHO consolidated guidelines on tuberculosis . Module 5: management of tuberculosis in children and adolescents. Geneva World health Organisation; 2022."},{"key":"2025121400300790000_15.4.e088543.19","article-title":"Six months therapy for tuberculous meningitis","volume":"9","author":"Jullien","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121400300790000_15.4.e088543.20","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJMe2200966","article-title":"Childhood Tuberculosis - Time for Shorter and Differentiated Treatment","volume":"386","author":"Pai","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121400300790000_15.4.e088543.21","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1097\/INF.0000000000003729","article-title":"Towards Shorter, Child-Friendly Regimens for Treatment of Tuberculosis Disease and Infection in Children","volume":"42","author":"Yuen","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"2025121400300790000_15.4.e088543.22","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/cid\/ciac208","article-title":"Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial","volume":"75","author":"Paradkar","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025121400300790000_15.4.e088543.23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab162"},{"key":"2025121400300790000_15.4.e088543.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.06.016"},{"key":"2025121400300790000_15.4.e088543.25","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.778"},{"key":"2025121400300790000_15.4.e088543.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-016-1470-x","article-title":"Na\u00efve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis","volume":"16","author":"Pouplin","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2025121400300790000_15.4.e088543.27","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.202"},{"key":"2025121400300790000_15.4.e088543.28","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/jac\/dkab336","article-title":"Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial","volume":"76","author":"Garcia-Prats","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025121400300790000_15.4.e088543.29","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025121400300790000_15.4.e088543.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201910-1960OC"},{"key":"2025121400300790000_15.4.e088543.31","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1783"},{"key":"2025121400300790000_15.4.e088543.32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00064-11"},{"key":"2025121400300790000_15.4.e088543.33","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1472-9792(08)70038-6","article-title":"The early bactericidal activity of anti-tuberculosis drugs: a literature review","volume":"88 Suppl 1","author":"Donald","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"key":"2025121400300790000_15.4.e088543.34","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/INF.0000000000002268","article-title":"Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis","volume":"38","author":"Purchase","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"2025121400300790000_15.4.e088543.35","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/cid\/ciy416","article-title":"Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis","volume":"67","author":"Garcia-Prats","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025121400300790000_15.4.e088543.36","doi-asserted-by":"crossref","unstructured":"Duong T , Brigden J , Simon Schaaf H , et al . A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis. NEJM Evid 2025;4. doi:10.1056\/EVIDoa2400190","DOI":"10.1056\/EVIDoa2400190"},{"key":"2025121400300790000_15.4.e088543.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2009.07.012"},{"key":"2025121400300790000_15.4.e088543.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70034-0"},{"key":"2025121400300790000_15.4.e088543.39","article-title":"Corticosteroids for managing tuberculous meningitis","volume":"2008","author":"Prasad","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121400300790000_15.4.e088543.40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7336.S71"},{"key":"2025121400300790000_15.4.e088543.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2010.03.025"},{"key":"2025121400300790000_15.4.e088543.42","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.33478","article-title":"A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults","volume":"7","author":"Mai","year":"2018","journal-title":"Elife"},{"key":"2025121400300790000_15.4.e088543.43","doi-asserted-by":"publisher","DOI":"10.1177\/0883073811398132"},{"key":"2025121400300790000_15.4.e088543.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2009.06.011"},{"key":"2025121400300790000_15.4.e088543.45","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70138-9"},{"key":"2025121400300790000_15.4.e088543.46","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.10.080010"},{"key":"2025121400300790000_15.4.e088543.47","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/cid\/ciw757","article-title":"Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies","volume":"64","author":"Marais","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025121400300790000_15.4.e088543.48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/QCO.0000000000000648","article-title":"Tuberculous meningitis: where to from here?","volume":"33","author":"Donovan","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2025121400300790000_15.4.e088543.49","unstructured":"World Health Organisation . Rapid communication on updated guidance on the management of tuberculosis in children and adolescents. Geneva; 2021. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240033450"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-088543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:30:17Z","timestamp":1765701017000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-088543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,2]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjopen-2024-088543"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088543","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}